Prognostic Factors in the First-Line Chemotherapy of Advanced Non-Squamous Non-Small Cell Lung Cancer Patients with Performance Status 2

被引：0
|
作者：
Hosokawa, Shinobu [1 ]
Bessho, Akihiro [1 ]
Nishii, Kazuya [1 ]
Fukamatsu, Nobuaki [1 ]
Ogata, Yoshiko [1 ]
Sakugawa, Makoto [1 ]
机构：
[1] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Prognostic factors; performance status 2; Advanced Non-Small Cell Lung Cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-043
引用
收藏
页码：S418 / S418
页数：1
相关论文
共 50 条
  • [1] EAGLES study: First-line Bevacizumab in Combination with Chemotherapy in Elderly Patients with Advanced, Metastatic, Non-squamous Non-small Cell Lung Cancer
    De Marinis, Filippo
    Bidoli, Paolo
    Luciani, Andrea
    Amoroso, Domenico
    Tonini, Giuseppe
    Bertolini, Alessandro
    Brandes, Alba A.
    Migliorino, Maria Rita
    Favaretto, Adolfo
    Gridelli, Cesare
    [J]. ANTICANCER RESEARCH, 2017, 37 (05) : 2457 - 2464
  • [2] Clinical Study of Pemetrexed as the First-line Treatment in Elderly Patients with Advanced Non-squamous Non-small Cell Lung Cancer
    Pu Xiaolin
    Wang Jun
    Li Wei
    Lu Binbin
    Wang Zhaoxia
    Yang Min
    Fan Weifei
    [J]. JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2013, 1 (04): : 205 - 209
  • [3] The potential cost-effectiveness of first-line immunotherapy plus chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
    Roth, Joshua A.
    Trung Nguyen
    Goulart, Bernardo H. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status
    Facchinetti, Francesco
    Mazzaschi, Giulia
    Barbieri, Fausto
    Passiglia, Francesco
    Mazzoni, Francesca
    Berardi, Rossana
    Proto, Claudia
    Cecere, Fabiana Letizia
    Pilotto, Sara
    Scotti, Vieri
    Rossi, Sabrina
    Del Conte, Alessandro
    Vita, Emanuele
    Bennati, Chiara
    Ardizzoni, Andrea
    Cerea, Giulio
    Migliorino, Maria Rita
    Sala, Elisa
    Camerini, Andrea
    Bearz, Alessandra
    De Carlo, Elisa
    Zanelli, Francesca
    Guaitoli, Giorgia
    Garassino, Marina Chiara
    Ciccone, Lucia Pia
    Sartori, Giulia
    Toschi, Luca
    Dall'Olio, Filippo Gustavo
    Landi, Lorenza
    Pizzutilo, Elio Gregory
    Bartoli, Gabriele
    Baldessari, Cinzia
    Novello, Silvia
    Bria, Emilio
    Cortinovis, Diego Luigi
    Rossi, Giulio
    Rossi, Antonio
    Banna, Giuseppe Luigi
    Camisa, Roberta
    Di Maio, Massimo
    Tiseo, Marcello
    [J]. EUROPEAN JOURNAL OF CANCER, 2020, 130 : 155 - 167
  • [5] EFFICIENCY OF CISPLATIN, PEMETREXED, AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR JAPANESE ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
    Shiraishi, Yoshimasa
    Hirai, Humihiko
    Yamaguchi, Masafumi
    Morodomi, Yosuke
    Toyozawa, Ryo
    Inamasu, Eiko
    Kojo, Miyako
    Toyokawa, Gouji
    Takenaka, Tomoyoshi
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S488 - S488
  • [6] Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer
    Xu, Bei
    Liu, Peng
    Yin, Yongmei
    Liu, Ping
    Shu, Yongqian
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (08) : 763 - 769
  • [7] Nutritional status changes in patients with advanced non-small cell lung cancer receiving first-line chemotherapy
    Wei Sun
    Shunfang Liu
    Ping Peng
    Dongbo Liu
    [J]. Oncology and Translational Medicine, 2018, 4 (02) : 54 - 57
  • [8] FDG-PET/CT to predict outcome of first-line chemotherapy plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer
    Usmanij, Edwin
    Natroshvili, Tinatin
    Timmer-Bonte, Johanna
    van der Drift, Miep
    Oyen, Wim
    Bussink, Johan
    De Geus-Oei, Lioe-Fee
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [9] Survival among advanced non-small cell lung cancer patients with poor performance status after first-line chemotherapy
    Salloum, Ramzi George
    Smith, Thomas J.
    Jensen, Gail
    Elston-Lafata, Jennifer
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
    F Grossi
    E Rijavec
    C Genova
    G Barletta
    F Biello
    C Maggioni
    G Burrafato
    C Sini
    M G Dal Bello
    K Meyer
    J Roder
    H Roder
    J Grigorieva
    [J]. British Journal of Cancer, 2017, 116 : 36 - 43
12345